Polyrizon Ltd (PLRZ)

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)July 2, 2026 8:29 AM
IH Market News NASARIX achieves positive biological safety results Shares of Polyrizon Ltd. (NASDAQ:PLRZ) gained 10% on Friday after the biotechnology company reported successful results from the biocompatibility evaluation programme for its NASARIX Allergy Blocker nasal spray. According to the company, all required biological safety assessments met their predefined acceptance criteria, marking another step forward in the product’s development. Testing completed under international regulatory standards Polyrizon said the evaluation programme was conducted in line with internationally recognised biological safety standards for medical devices, including the ISO 10993 series, U.S. Food and Drug Administration guidance and relevant European regulatory requirements. The assessment covered a range of biological safety endpoints for the drug-free, mucoadhesive nasal spray, including cytotoxicity, sensitisation, irritation, material-mediated pyrogenicity and acute systemic toxicity. Long-term systemic toxicity was evaluated through a toxicological risk assessment performed in accordance with ISO 10993-17. Assessment based on final product configuration The company said the biocompatibility review was carried out using the final NASARIX product configuration and incorporated evaluations of the formulation, manufacturing process, packaging materials and anticipated patient exposure. “Achieving positive results across all required biological safety assessments represents a significant milestone in our development program and further supports the biocompatibility safety profile of NASARIX as we continue advancing its clinical and regulatory pathway,” said Tomer Izraeli, Chief Executive Officer of Polyrizon. Milestone supports path toward commercialisation Polyrizon noted that the programme was developed within a risk management framework consistent with ISO 10993-1 and ISO 14971. The successful completion of the evaluation supports the continued clinical and regulatory development of NASARIX as the company works toward the potential commercial launch of its nasal barrier technology for people with seasonal allergies. Polyrizon stock priceThe post Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) appeared first on US Editors. Original: Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)

Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable ProtectionMay 11, 2026 7:25 AM
PR Newswire (US) In light of the growing challenges posed by emerging respiratory threats, including recent Hantavirus, Polyrizon is advancing a biophysical barrier technology that may offer immediate, non-specific defense at the nasal gatewayHONG KONG, May 11, 2026 /PRNewswire/ -- Recent World Health Organization reports of Hantavirus clusters, including clusters of severe acute respiratory illness, have once again served as a stark reminder: the next major viral threat is never far away. Whether it is Hantavirus, a novel coronavirus variant, or an unexpected influenza strain, the pattern is consistent. Outbreaks emerge quickly, and the window for effective intervention is narrow.In these critical early weeks, before pathogen-specific vaccines or therapeutics can be developed, tested, and scaled, healthcare systems and governments are left with limited tools. This recurring vulnerability creates a clear market need for complementary, broad-spectrum solutions that can be deployed immediately - buying precious time and reducing risk until targeted countermeasures arrive.Polyrizon Ltd. (Nasdaq: PLRZ), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, is advancing a new category of non-specific defenses designed to address exactly this challenge.Polyrizon's Capture&Contain™ platform was designed precisely for this gap.The technology utilizes proprietary polysaccharide formulations that rapidly form a thin, protective biophysical layer on the nasal mucosa - the primary entry point for most respiratory viruses. Rather than relying on pharmacological or virus-specific mechanisms, the platform creates a mechanical barrier that interferes with the ability of viruses to reach and infect host cells.Laboratory studies conducted under controlled in-vitro conditions, including dynamic models simulating viral exposure, have demonstrated that these formulations can limit viral-host interaction across multiple respiratory virus families, such as influenza  and coronaviruses. Treated cell cultures consistently showed better preservation of cell viability compared to untreated controls, supporting the barrier's potential effectiveness under laboratory conditions. Similar encouraging results were observed with different influenza variants, reinforcing the platform's broad, non-specific mode of action.This approach offers several compelling advantages for investors and public health strategists alike:Immediate deployability - no need to wait for strain-specific developmentBroad applicability - potentially effective against both known and yet-to-emerge respiratory pathogensFlexible platform - the same core technology can be adapted quickly to new scenariosComplementary positioning - works alongside (not in competition with) future vaccines and antiviralsPL-16, Polyrizon's lead Viral Blocker product candidate based on the Capture&Contain™ technology, is currently advancing through development. While still pre-clinical, the platform has the potential to represent a differentiated opportunity in the rapidly growing field of pandemic preparedness and respiratory protection.As the world faces increasingly frequent and unpredictable viral outbreaks - exemplified by the recent Hantavirus clusters - technologies that provide fast, adaptable, and non-specific protection are shifting from "nice-to-have" to potentially strategic assets. Polyrizon aims to position itself at the forefront of this emerging category, offering a potentially valuable tool for governments, healthcare systems, and organizations seeking to strengthen their resilience against tomorrow's threats.While further clinical evaluation will be required, the early scientific foundation, combined with the clear and growing market need, potentially positions the Capture&Contain™ platform as an attractive opportunity in the evolving infectious disease defense landscape.Paid Promotional DisclosureThis press release constitutes a paid promotional communication. Polyrizon Ltd.. ("Polyrizon") has engaged a third-party service provider to provide investor awareness and promotional services, including the dissemination of this press release, and has paid a fee for such services. Polyrizon exercises editorial control over the content of this press release but does not control how, when, or to whom the information is distributed by such third party.This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Polyrizon. Investing in Polyrizon's securities involves significant risks, and readers are encouraged to review Polyrizon's filings with the U.S. Securities and Exchange Commission available at www.sec.gov before making any investment decision.Pulse Equity DisclaimerThis article was produced by Pulse Equity, a brand / division of MR Solutions Limited (Hong Kong), and is provided for general informational and promotional purposes only. The content does not constitute investment advice, financial advice, medical advice, or a recommendation to buy, sell, or hold any securities, nor does it constitute an offer or solicitation in any jurisdiction.Pulse Equity is not a registered broker-dealer, investment adviser, securities analyst, or medical professional. The information presented is based on publicly available sources and statements believed to be reliable at the time of publication; however, Pulse Equity makes no representations or warranties as to the accuracy or completeness of the information and has not independently verified all data referenced.Certain content published by Pulse Equity may be sponsored or compensated by the company discussed or its affiliates, which may create a potential conflict of interest. Readers are encouraged to conduct their own independent research and consult qualified financial, legal, medical, or other professional advisers before making any investment or health- related decisions.Forward-looking statements referenced in this article are subject to risks and uncertainties, and actual results may differ materially. Past performance is not indicative of future results.For full disclosures, risk factors, and forward-looking statements, please visit: 
https://pulse-equity.com/disclaimer/Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, forward-looking statements in this press release the timing and progress of Polyrizon's clinical trials, how Polyrizon's Capture&Contain™ platform has the potential to represent a differentiated opportunity in the rapidly growing field of pandemic preparedness and respiratory protection, how technologies that provide fast, adaptable, and non-specific protection are shifting from "nice-to-have" to potentially strategic assets, how Polyrizon aims to position itself at the forefront of this emerging category, offering a potentially valuable tool for governments, healthcare systems, and organizations seeking to strengthen their resilience against tomorrow's threats and the Capture&Contain™ platform's potential position as an attractive opportunity in the evolving infectious disease defense landscape. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting Polyrizon, reference is made to Polyrizon's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in Polyrizon's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. Polyrizon assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If Polyrizon does update one or more forward-looking statements, no inference should be drawn that Polyrizon will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.Contact: 
Pulse Equity, 
Office@Pulse-Equity.com View original content:https://www.prnewswire.com/news-releases/pulse-equity-emerging-outbreaks--polyrizons-approach-to-broad-and-rapidly-deployable-protection-302768133.htmlSOURCE Pulse Equity Original: Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy BlockerFebruary 17, 2026 11:32 AM
PR Newswire (US)

HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™. This included trademark screening in the U.S. and European markets and represents a practical step toward potential commercialization for the pre-clinical-stage Israeli biotech.Polyrizon is assessing whether NASARIX™ could emerge as a meaningful advancement in allergy treatment.The Allergic Rhinitis ChallengeAllergic rhinitis- often called hay fever- remains a widespread and burdensome condition, affecting an estimated 10–30% of the global population. Symptoms, such as sneezing, nasal congestion, itching, and runny nose, disrupt sleep, work, and daily life, with rising prevalence linked to urbanization, pollution, and climate-driven pollen increases. In the U.S., it impacts over 60 million people each year, contributing to significant healthcare spending and lost productivity.The global market for allergic rhinitis treatments is substantial and steadily expanding. Recent estimates value it at around USD 13.08 billion in 2025, projected to reach USD 18.81 billion by 2035 at a compound annual growth rate (CAGR) of 3.7%. Other analyses align closely, forecasting growth from USD 12.24 billion in 2024 to USD 16.97 billion by 2033, driven by demand for intranasal therapies and non-sedating alternatives.Most options are reactive - they relieve symptoms after allergens trigger inflammation. Preventive strategies exist, but few directly block exposure at the nasal entry point in a convenient, drug-free way.NASARIX™'s Differentiated ApproachNASARIX™ is a nasal spray based on Polyrizon's Capture and Contain™ (C&C) hydrogel technology. When applied, it forms a thin, bio-adhesive barrier that physically traps allergens (such as pollen, dust mites, pet dander) before they reach the sensitive epithelial nasal tissue. Key claimed advantages include:Drug-free and non-pharmacological — no steroids, antihistamines, or systemic effects.Moisturizing and comfortable for extended use.Preclinical lab data show better allergen-blocking than standard comparators (e.g., hydroxypropyl methylcellulose barriers).If human trials, once initiated, confirm these benefits, it has the potential to appeal to users seeking natural, preventive protection- particularly during peak seasons or in high-exposure environments- without the side effects common in traditional meds.As of February 2026, the NASARIX™ program continues to advance with encouraging momentum. While human clinical data on efficacy and safety are expected for later this year, Polyrizon has already initiated a key human factors and usability study on January 22, 2026. This important work, fully aligned with FDA guidance, has been shown to validate the product's clear instructions, intuitive labeling, and seamless user experience- steps that significantly strengthen the regulatory foundation and reduce future risks. With this progress in place, the company is expected to begin clinical trials in Q3 2026. Positioning NASARIX™ as a medical device further brightens the potential path ahead, offering a more streamlined and efficient approval route compared to traditional drug development, which brings the possibility of reaching patients, following FDA approval, much sooner.In a large and steadily growing market hungry for fresh, user-friendly innovations, NASARIX™ represents promise as a proactive, comfortable addition to allergy care. With steady progress, a focused core technology, and upcoming milestones, the company is optimistic that NASARIX™ may potentially evolve into a welcome new option for allergy sufferers looking for better everyday protection.Looking AheadIn short, NASARIX™ has evidenced solid conceptual promise as a preventive, user-friendly addition to allergy care. Early 2026 milestones, like branding and usability work, keep the program advancing. The real test will come with human trial results, which are expected to commence later this year.Paid Promotional DisclosureThis press release constitutes a paid promotional communication. Polyrizon Ltd.. ("Polyrizon") has engaged a third-party service provider to provide investor awareness and promotional services, including the dissemination of this press release, and has paid a fee for such services. Polyrizon exercises editorial control over the content of this press release but does not control how, when, or to whom the information is distributed by such third party.This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Polyrizon. Investing in Polyrizon's securities involves significant risks, and readers are encouraged to review Polyrizon's filings with the U.S. Securities and Exchange Commission available at www.sec.gov before making any investment decision.
For more information about Polyrizon, please visit https://polyrizon-biotech.com.Moonage Media- DisclaimerThis article was produced by Moonage Media, a brand / division of MR Solutions Limited (Hong Kong), and is provided for general informational and promotional purposes only. The content does not constitute investment advice, financial advice, medical advice, or a recommendation to buy, sell, or hold any securities, nor does it constitute an offer or solicitation in any jurisdiction.Moonage Media is not a registered broker-dealer, investment adviser, securities analyst, or medical professional. The information presented is based on publicly available sources and statements believed to be reliable at the time of publication; however, Moonage Media makes no representations or warranties as to the accuracy or completeness of the information and has not independently verified all data referenced.Certain content published by Moonage Media may be sponsored or compensated by the company discussed or its affiliates, which may create a potential conflict of interest. Readers are encouraged to conduct their own independent research and consult qualified financial, legal, medical, or other professional advisers before making any investment or health-related decisions.Forward-looking statements referenced in this article are subject to risks and uncertainties, and actual results may differ materially. Past performance is not indicative of future results.For full disclosures, risk factors, and forward-looking statements, please visit: https://moonage.media/disclaimer/Contact:Moonage Media
Office@Moonage.media 



View original content:https://www.prnewswire.com/news-releases/moonage-media-spotlights-polyrizon-nasdaq-plrz-unveils-nasarix-drug-free-allergy-blocker-302689664.htmlSOURCE Moonage Media

Original: Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon shares gain on plan to buy majority stake in private aviation companyFebruary 4, 2026 10:44 AM
IH Market News
Polyrizon Ltd. (NASDAQ:PLRZ) shares moved about 2% higher after the pre-clinical biotechnology company disclosed plans to acquire a controlling interest in Arrow Aviation Ltd., a privately held global aviation services provider.Under a non-binding memorandum of understanding, Polyrizon intends to purchase a 51% stake in Arrow Aviation for roughly $5.8 million (NIS 18,000,000) in cash. The proposed deal would mark a notable strategic step for Polyrizon, extending its activities beyond biotechnology into the private aviation industry.According to Polyrizon, Arrow Aviation generates approximately $19 million in unaudited annual revenue and around $3 million in adjusted EBITDA. The company operates a fleet of executive aircraft offering VIP charter services for business and leisure customers, alongside specialized operations such as medical evacuation flights, air rescue missions and cargo transport.“We believe that this strategic move, upon completion, represents an exciting diversification opportunity for Polyrizon, allowing us to leverage our strong financial position to enter the dynamic private aviation market,” said Tomer Izraeli, CEO of Polyrizon.The outlined transaction also includes additional elements, such as the transfer of a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation and the cancellation of certain shareholder debts in exchange for convertible notes. The MOU further ??????????? mutual call and put options on the remaining 49% stake in Arrow Aviation, which could be exercised after two years.Polyrizon said it expects to finalize a binding agreement within 30 days, subject to completion of due diligence and standard closing conditions.Polyrizon stock price

Original: Polyrizon shares gain on plan to buy majority stake in private aviation company

Running up into close,up 67% happy new year indeed 🎉

Thanks...Happy New Year to you as well...🥳

Thanks bro,appreciate you!
Happy new year!

Hey tw0122, thought u might want to take a look back again, volume sucks but maybe something brewing because they aren’t loaning shares to short. Anyway…just wanted you to know bro. Happy new year!!

Thanks...🥳...Not in right now but watching...SMX...DGNX...BDRX ...all went Zero Borrow this morning...

It’s zero borrow again,as of 8 am

The Israel-based biotechnology company on Wednesday announced preclinical test data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved intranasal naloxone spray currently on the market

$21 let's go $500

$18.66

$500 is possible 

The Israel-based biotechnology company on Wednesday announced preclinical test data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved intranasal naloxone spray currently on the market.Using an ex-vivo rabbit nasal mucosa model, researchers applied each formulation to mucosal tissue and washed it with Simulated Nasal Electrolyte Solution over a 30-minute period.Compared with the commercial product, Polyrizon's Trap and Target hydrogel showed higher fluorescence marker values, with differences reaching statistical significance (p < 0.0001, two-way ANOVA).Tomer Izraeli, CEO of Polyrizon, said, "The ability to significantly outperform an existing marketed product in mucoadhesion is an important milestone as we continue advancing our Naloxone program."Polyrizon also reached a major manufacturing upscaling milestone for its nasal-spray platform, moving from small-batch laboratory production to larger-scale controlled manufacturing to validate key parameters of its PL-14, a proprietary bio-adhesive formulation.PLRZ is down 99.74% year-to-date but has rebounded 45.88% over the past six months. The company has a market capitalization of $7.39 million.

Yup...🥳

PLRZ...$17...🥳...Another Zero Borrow Runner...

georgie18

Member Level
Re: georgie18 post# 482

Tuesday, December 02, 2025 1:37:30 PM

Post#
483
of 498
PLRZ...$7.94...🥳...Halted ...Watching for another entry...

georgie18

Member Level
Re: georgie18 post# 707456

Tuesday, December 02, 2025 12:31:56 PM

Post#
707710
of 707723
PLRZ...$7.40...🥳...Off my $3.24 Alert...All out here...

georgie18

Member Level
Re: georgie18 post# 469

Friday, November 28, 2025 12:59:23 PM

Post#
470
of 481
PLRZ...$3.24...🥳...Hit $3.64...Post 1/6 R/S...

georgie18

Member Level
Re: georgie18 post# 707301

Thursday, November 27, 2025 10:57:24 AM

Post#
707303
of 707454
PLRZ...1/6 R/S on Friday...🥳...Micro Float...

georgie18

Member Level
Re: georgie18 post# 466

Thursday, November 27, 2025 10:27:33 AM

Post#
467
of 469
PLRZ...52...🥳... https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Took starter at .68...added 50 range shares ...will add up or down to build a strong position...

https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Up 200%

$21

It reverse split twice so what $500 next target 

21 

$20

$18

$17.49

$17

16.32 Santa's helpers here

ctive charts, live options flow, and more. https://investorshub.advfn.com/secure/reguser3.aspx7.61 0.28 (3.82%)After HoursLast Updated:18:08:55Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone productDecember 03 2025 - 9:28AM
https://twitter.com/sharehttp://www.facebook.com/sharer.php?s=100&p[url]=https%3A%2F%2Finvestorshub.advfn.com%2Fstock-market%2FNASDAQ%2Fpolyrizon-PLRZ%2Fstock-news%2F97369369%2Fpolyrizon-reports-positive-mucoadhesion-results-fo
Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced compelling new preclinical data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved and marketed intranasal naloxone spray product.Using an established ex-vivo rabbit nasal mucosa model, researchers evaluated the persistence of Polyrizon’s hydrogel formulation versus commercial product by applying each formulation to mucosal tissue and washing with Simulated Nasal Electrolyte Solution (SNES) over a 30-minute period. Quantification of residual fluorescence revealed that Polyrizon’s hydrogel maintained higher values of the fluorescence marker when compared to the commercial product, with differences reaching high statistical significance (p < 0.0001, two-way ANOVA), indicating notably stronger and more durable mucosal retention.The results showed that Polyrizon’s Trap and Target ™ (T&T) hydrogel exhibited significantly higher mucoadhesion levels compared to the commercial product, supporting potentially prolonged contact at the nasal deposition site and potentially enhancing bioavailability.Improved mucoadhesion is a critical factor for intranasal drug delivery - particularly for emergency treatments such as opioid overdose reversal - because enhanced residence time at the nasal deposition site can support more reliable absorption and potentially faster onset of action.“We believe that these outcomes further validate the potential of our T&T hydrogel platform and highlight its unique advantages in intranasal drug delivery,” said Tomer Izraeli, CEO of Polyrizon. “The ability to significantly outperform an existing marketed product in mucoadhesion is an important milestone as we continue advancing our Naloxone program.”This new dataset builds directly on the previously reported encouraging stability results, which demonstrated the robustness of Polyrizon’s formulation under various storage conditions. Collectively, stability plus mucoadhesion performance reinforce the potential of Polyrizon’s T&T technology to deliver a safer, more reliable, and more effective intranasal Naloxone product.

Ok almost $15.49 sell sell time 

$16 

$14

$13 💥 boom

PLRZ...$7.94...🥳...Halted ...Watching for another entry...

georgie18

Member Level
Re: georgie18 post# 707456

Tuesday, December 02, 2025 12:31:56 PM

Post#
707710
of 707723
PLRZ...$7.40...🥳...Off my $3.24 Alert...All out here...

georgie18

Member Level
Re: georgie18 post# 469

Friday, November 28, 2025 12:59:23 PM

Post#
470
of 481
PLRZ...$3.24...🥳...Hit $3.64...Post 1/6 R/S...

georgie18

Member Level
Re: georgie18 post# 707301

Thursday, November 27, 2025 10:57:24 AM

Post#
707303
of 707454
PLRZ...1/6 R/S on Friday...🥳...Micro Float...

georgie18

Member Level
Re: georgie18 post# 466

Thursday, November 27, 2025 10:27:33 AM

Post#
467
of 469
PLRZ...52...🥳... https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Took starter at .68...added 50 range shares ...will add up or down to build a strong position...

https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

PLRZ...$7.40...🥳...Off my $3.24 Alert...All out here...

georgie18

Member Level
Re: georgie18 post# 469

Friday, November 28, 2025 12:59:23 PM

Post#
470
of 481
PLRZ...$3.24...🥳...Hit $3.64...Post 1/6 R/S...

georgie18

Member Level
Re: georgie18 post# 707301

Thursday, November 27, 2025 10:57:24 AM

Post#
707303
of 707454
PLRZ...1/6 R/S on Friday...🥳...Micro Float...

georgie18

Member Level
Re: georgie18 post# 466

Thursday, November 27, 2025 10:27:33 AM

Post#
467
of 469
PLRZ...52...🥳... https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Took starter at .68...added 50 range shares ...will add up or down to build a strong position...

https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Thanks...Late start today...🥳

Hahaha watxh it move from $6 to $7 your getting slower by the day

7.81 magnitude quake magnetic 🧲

Here we go

Fake traders never guess right

Post split monster

6.64 magnitude magnetic 🧲

PLRZ 5.80. Watch and learn fake traders

Up to $6

Out )4.90s 

Quick flip in 3.30s

PLRZ...$3.24...🥳...Hit $3.64...Post 1/6 R/S...

georgie18

Member Level
Re: georgie18 post# 707301

Thursday, November 27, 2025 10:57:24 AM

Post#
707303
of 707454
PLRZ...1/6 R/S on Friday...🥳...Micro Float...

georgie18

Member Level
Re: georgie18 post# 466

Thursday, November 27, 2025 10:27:33 AM

Post#
467
of 469
PLRZ...52...🥳... https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Took starter at .68...added 50 range shares ...will add up or down to build a strong position...

https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

PLRZ...1/6 R/S on Friday...🥳...Micro Float...

georgie18

Member Level
Re: georgie18 post# 466

Thursday, November 27, 2025 10:27:33 AM

Post#
467
of 469
PLRZ...52...🥳... https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Took starter at .68...added 50 range shares ...will add up or down to build a strong position...

https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

PLRZ RS tomorrow

PLRZ...52...🥳... https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

Took starter at .68...added 50 range shares ...will add up or down to build a strong position...

https://finviz.com/news/220972/polyrizon-demonstrates-reversible-broad-spectrum-viral-blocking-by-its-intranasal-barrier-forming-formulation

PLRZ...68...🥳...Took starter in the .65 range... https://schrts.co/tzqnaYUj ...Float listed as 6 Million...

Think I sold this one back in July that's when Plrz and Ptpi were hot